Avecho Signs Licensing Agreement with Swiss Off-Patient Medicine Provider

MT Newswires Live03-03

Avecho Biotechnology (ASX:AVE) has signed a ten-year exclusive licensing agreement with Switzerland-based Sandoz Group AG for the commercialization of its cannabidiol (CBD) capsule aimed at treating insomnia in Australia, according to a Monday filing with the Australian bourse.

Under the deal, Avecho will receive an upfront payment of $3 million, milestone payments of up to $16 million, and royalties ranging from 14% to 19% on net sales, the filing said.

Avecho will continue funding the ongoing Phase III clinical trial and collaborate with Sandoz on regulatory approval from the Therapeutic Goods Administration, the filing added.

Once approved, Sandoz will market and distribute the product in Australia and Avecho will retain commercialization rights in all other territories, with Sandoz holding a right of first refusal, the company said.

Shares of the company fell 14% on market close.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2516088125?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-03 14:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516088125","market":"fut","top_or_hot":-1,"title":"Avecho Signs Licensing Agreement with Swiss Off-Patient Medicine Provider","media":"MT Newswires Live","content":"<html><body><p> Avecho Biotechnology (ASX:AVE) has signed a ten-year exclusive licensing agreement with Switzerland-based Sandoz Group AG for the commercialization of its cannabidiol (CBD) capsule aimed at treating insomnia in Australia, according to a Monday filing with the Australian bourse.</p><p>Under the deal, Avecho will receive an upfront payment of $3 million, milestone payments of up to $16 million, and royalties ranging from 14% to 19% on net sales, the filing said.</p><p>Avecho will continue funding the ongoing Phase III clinical trial and collaborate with Sandoz on regulatory approval from the Therapeutic Goods Administration, the filing added.</p><p>Once approved, Sandoz will market and distribute the product in Australia and Avecho will retain commercialization rights in all other territories, with Sandoz holding a right of first refusal, the company said.</p><p>Shares of the company fell 14% on market close.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avecho Signs Licensing Agreement with Swiss Off-Patient Medicine Provider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvecho Signs Licensing Agreement with Swiss Off-Patient Medicine Provider\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-03 14:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Avecho Biotechnology (ASX:AVE) has signed a ten-year exclusive licensing agreement with Switzerland-based Sandoz Group AG for the commercialization of its cannabidiol (CBD) capsule aimed at treating insomnia in Australia, according to a Monday filing with the Australian bourse.</p><p>Under the deal, Avecho will receive an upfront payment of $3 million, milestone payments of up to $16 million, and royalties ranging from 14% to 19% on net sales, the filing said.</p><p>Avecho will continue funding the ongoing Phase III clinical trial and collaborate with Sandoz on regulatory approval from the Therapeutic Goods Administration, the filing added.</p><p>Once approved, Sandoz will market and distribute the product in Australia and Avecho will retain commercialization rights in all other territories, with Sandoz holding a right of first refusal, the company said.</p><p>Shares of the company fell 14% on market close.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XAO.AU","symbol_name":"标普/澳交所 普通股指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2516088125","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516088125","pubTimestamp":1740984752,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Avecho Biotechnology  has signed a ten-year exclusive licensing agreement with Switzerland-based Sandoz Group AG for the commercialization of its cannabidiol  capsule aimed at treating insomnia in Australia, according to a Monday filing with the Australian bourse.Under the deal, Avecho will receive an upfront payment of $3 million, milestone payments of up to $16 million, and royalties ranging from 14% to 19% on net sales, the filing said.Avecho will continue funding the ongoing Phase III clinical trial and collaborate with Sandoz on regulatory approval from the Therapeutic Goods Administration, the filing added.Once approved, Sandoz will market and distribute the product in Australia and Avecho will retain commercialization rights in all other territories, with Sandoz holding a right of first refusal, the company said.Shares of the company fell 14% on market close.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XAO.AU":"标普/澳交所 普通股指数","XJO.AU":"标普/澳交所 200指数","CBD":"Companhia Brasileira de Distribu","BK4113":"食品零售","AVE.AU":"AVECHO BIOTECHNOLOGY LTD","XKO.AU":"标普/澳交所 300指数","BK7096":"制药"},"translate_title":"Avecho与瑞士门诊药物提供商签署许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVE.AU":0.9,"CBD":1,"XAO.AU":0.9,"XJO.AU":0.9,"XKO.AU":0.9},"content_text":"Avecho Biotechnology (ASX:AVE) has signed a ten-year exclusive licensing agreement with Switzerland-based Sandoz Group AG for the commercialization of its cannabidiol (CBD) capsule aimed at treating insomnia in Australia, according to a Monday filing with the Australian bourse.Under the deal, Avecho will receive an upfront payment of $3 million, milestone payments of up to $16 million, and royalties ranging from 14% to 19% on net sales, the filing said.Avecho will continue funding the ongoing Phase III clinical trial and collaborate with Sandoz on regulatory approval from the Therapeutic Goods Administration, the filing added.Once approved, Sandoz will market and distribute the product in Australia and Avecho will retain commercialization rights in all other territories, with Sandoz holding a right of first refusal, the company said.Shares of the company fell 14% on market close.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2516088125"}